Plain-English translation of NCT06843447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called (R-DXd) for people with ovarian cancer that has come back after previous chemotherapy. The medication may be given alone or combined with other cancer drugs. The study has two main phases: first, researchers will test different doses to find the safest and most effective amount, and then they will expand the trial to test this dose in more patients.
Ovarian cancer often returns after initial treatment, and many patients need new options. This medication works in a different way than standard chemotherapy, and researchers hope it may help people whose cancer has become resistant to platinum-based drugs or who need additional treatment choices.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous (IV) infusions of the medication at a cancer treatment center, possibly combined with other chemotherapy drugs, depending on which study group you're assigned to. The main chemotherapy partner drugs are given for up to 6 cycles (about 4 months), while the new medication continues until your cancer progresses or you need to stop for other reasons. You will have regular blood tests, imaging scans, and visits with your doctor to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States